At this time, how are you using MRD testing for clinical management of patients with multiple myeloma?

Off a clinical protocol, I only routinely use MRD (clonoSEQ) in a very specific setting.

That setting is low risk patients who have received autologous transplant as part of first line therapy and did well. Specifically, if the patient's response to first line therapy is VGPR or better at day+60, then I schedule a bone marrow with MRD analysis at day+100. If the patient is MRD negative and PET/CT negative at day+100, I advise the patient to avoid lenalidomide maintenance altogether. As you can i...